Ethicon Endo-Surgery has cited a shift in its strategic priorities within gastroenterology and other areas as the reason for ending the relationship.
InScope will pay Given Imaging $7.6 million in fees associated with the termination. InScope will continue to support reimbursement activities for PillCam ESO and maintain its market development field force for up to six months. InScope has also agreed to continue to fund ongoing clinical trials associated with esophageal diseases.
Homi Shamir, president and CEO of Given Imaging, said: “With the release of PillCam ESO 2, the improved ingestion procedure, a growing body of positive clinical data and reimbursement coverage momentum, we are confident about PillCam ESO’s potential. At the start of this year, Given and InScope adjusted the way we worked together in the field and, as a result, our US sales and marketing teams have worked side-by-side with InScope’s market development group to educate gastroenterologists and hepatologists.”